Dr. Stanley Schwartz addresses the question of, “Where do we go from here?” regarding the beta-cell centric approach. He notes that there are two ways to approach the question — grassroots and a top-down approach — and says that both avenues should be pursued. He hopes that his his presentation at the 2014 ADA will provide the stimulus to bring the different medical organizations together in a room to come up with a viable classification of diabetes. Hopefully, this will allow clinicians to ultimately provide better care for their patients….
More videos in this series with Dr. Schwartz:
- Stanley Schwartz, MD, FACP, FACE: Introduction, ADA 2014
- A New Way of Classifying Diabetes – The Beta-Cell Centric Approach
- Picking the Right Drugs for the Right Patients
- Positive Effects of More Aggressive Treatment
- Why Sulfonylureas Should No Longer Be Used
- How Do You Determine Beta Cell Function?
- Prescribing Medications for Prediabetes
Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
He is also part of the following speaker’s bureaus: Merck; Eli Lilly; Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a frequent contributor to our newsletters. You can find all of Dr. Schwartz’s Diabetes In Control articles here.
Featuring Stanley Schwartz, MD, FACP, FACE